mRNA technology promises a long-awaited turning point in cancer treatment

mRNA technology promises a long-awaited turning point in cancer treatment
mRNA technology promises a long-awaited turning point in cancer treatment

mRNA technology promises a long-awaited turning point in cancer treatment

mRNA technology promises a long-awaited turning point in cancer treatment

The medical and pharmaceutical community continues to embrace new technologies, starting with mRNA, which rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to more personalized and effective treatment, as messenger RNA gives instructions to the patient’s cells on how to fight diseases like cancer.

Moderna Inc (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) have joined forces to advance cancer treatment with an experimental mRNA vaccine that will be used in combination with Merck’s blockbuster immunotherapy drug Keytruda. After promising mid-stage trial results in the fight against melanoma, the duo is also conducting a late-stage study to confirm its findings and expand its research scope to other cancers, starting with a non-small cell form of lung cancer. But mRNA technology is also being used to revolutionize cancer diagnostics.

Advances in early detection of cancer.

Mainz Biomed NV (NASDAQ: MYNZ), a molecular genetic diagnostics company specializing in early cancer detection, today reviewed its key achievements of the first half of the year. Its flagship product, the ColoAlert home colorectal cancer screening test, is already available across Europe. At ASCO 2024, Mainz Biomed confirmed the results of its previous ColoFuture and eAArly DETECT studies. The pooled study was a third consecutive confirmation of the effectiveness of its tool in detecting colorectal cancer and precancerous lesions. By integrating the fecal immunochemical test with proprietary mRNA biomarkers and advanced AI and machine learning algorithms, Mainz Biomed’s test demonstrated a 92% detection rate for colorectal cancer as well as 82% sensitivity for advanced adenomas, which are a known precursor to cancer, including a 95.8% detection rate for high-grade dysplasia. Although CRC is the cancer with the second highest death rate in the United States and Europe, it is also the most preventable cancer, with survival rates exceeding 90% when detected early.

But Mainz Biomed went one step further, because the detection of lesions in a precancerous stage can change the entire CRC diagnostics, as it allows the patient to be treated before the polyps even progress to a cancerous stage. With its innovative approach and a positive result of the FDA study, Mainz Biomed has the potential to shake up the CRC diagnostic screening landscape and set a new gold standard.

In advance of its FDA approval trial, Mainz Biomed was also awarded a Poster of Distinction at Digestive Disease Week presenting data from its eAArly DETECT trial. The poster showed the study’s results with a sensitivity of 97% for colon cancer and 82% for advanced precancerous lesions. Mainz Biomed’s results for the six-month period ending June 30, 2024 are scheduled to be published in September.

Merck and Merck promise advances in the treatment of more than one type of cancer.

Merck and Moderna’s combined treatment showed strong results in patients diagnosed with melanoma. In a mid-stage study involving 157 patients, their combined treatment resulted in an overall survival rate of 96% after two and a half years, while Keytruda alone resulted in a survival rate of 90.2%. In addition, 75% of patients who received the combined treatment of the experimental mRNA vaccine and Keytruda survived relapse-free, while that number dropped to 55.6% for patients who received Keytruda alone. Moderna and Merck’s revolutionary cancer treatment represents a potential revolution on the oncology front.

Cancer is a very complex disease that occurs in more than 200 different types. As a result, medicine and science have been searching for a cure for far too long, marking cancer as a type of disease that we may never be able to completely cure. But with the help of mRNA, a more efficient treatment is on the horizon and finally a turning point in cancer treatment. Overall, it seems that by using new technologies, pharmaceutical companies finally have the tool to redefine cancer treatment.

DISCLAIMER: This content is for informational purposes only. It does not constitute investment advice.

This article was written by an unpaid outside contributor. It does not represent Benzinga’s reporting and has not been edited for content or content.

“THE SECRET WEAPON OF ACTIVE INVESTORS” Up your stock game with the #1 trading tool for “news and everything else”: Benzinga Pro – Click here to start your 14-day trial now!

Want to get the latest stock analysis from Benzinga?

This article, “mRNA technology promises a long-awaited turning point in cancer treatment,” originally appeared on

© 2024 Benzinga does not provide investment advice. All rights reserved.

Leave a Reply

Your email address will not be published. Required fields are marked *